Readings Newsletter
Become a Readings Member to make your shopping experience even easier.
Sign in or sign up for free!
You’re not far away from qualifying for FREE standard shipping within Australia
You’ve qualified for FREE standard shipping within Australia
The cart is loading…
Managing the Drug Discovery Process, Second Edition thoroughly examines the current state of pharmaceutical research and development by providing chemistry-based perspectives on biomedical research, drug hunting and innovation. The book also considers the interplay of stakeholders, consumers and the drug firm with attendant factors, including those that are technical, legal, economic, demographic, political, social, ecological and infrastructural. This new edition takes a closer look at increasing pre-approval costs for new drugs and examines not only why these increases occur, but also how they can be overcome to ensure a robust pharmacoeconomic future.
Since drug research can be a high-risk, high-payoff industry, it is important to researchers to effectively and strategically manage the drug discovery process. All chapters in this new release have been revised and expanded with new discussions on genetic and epigenetic advances, including CRISPR, exosomes, immuno-oncology approaches, including checkpoint inhibitors and CAR-T, antibiotics, entrepreneurship, and AI.
$9.00 standard shipping within Australia
FREE standard shipping within Australia for orders over $100.00
Express & International shipping calculated at checkout
Managing the Drug Discovery Process, Second Edition thoroughly examines the current state of pharmaceutical research and development by providing chemistry-based perspectives on biomedical research, drug hunting and innovation. The book also considers the interplay of stakeholders, consumers and the drug firm with attendant factors, including those that are technical, legal, economic, demographic, political, social, ecological and infrastructural. This new edition takes a closer look at increasing pre-approval costs for new drugs and examines not only why these increases occur, but also how they can be overcome to ensure a robust pharmacoeconomic future.
Since drug research can be a high-risk, high-payoff industry, it is important to researchers to effectively and strategically manage the drug discovery process. All chapters in this new release have been revised and expanded with new discussions on genetic and epigenetic advances, including CRISPR, exosomes, immuno-oncology approaches, including checkpoint inhibitors and CAR-T, antibiotics, entrepreneurship, and AI.